AcuCort reports positive outcome of the expert group work
AcuCort AB (Spotlight Stock Market: ACUC) today reports a positive view, concluding that the outcome of the second bioequivalence study for the US is not considered an obstacle for a market application for US registration of the company’s drug candidate ISICORT[®].As previously announced in a press release (November 8, 2019) AcuCort has appointed an expert group with the task to evaluate the results of the second study for the US market, with non-fasting patients,